CORDIS
EU research results

CORDIS

English EN

Innovative Nanoformulation of Antimicrobial Peptides to Treat Bacterial Infectious Diseases

Project information

Grant agreement ID: 604182

Status

Closed project

  • Start date

    1 December 2013

  • End date

    30 November 2017

Funded under:

FP7-NMP

  • Overall budget:

    € 10 348 954,90

  • EU contribution

    € 7 945 494

Coordinated by:

RISE RESEARCH INSTITUTES OF SWEDEN AB

Sweden

Objective

Resistance to traditional antibiotics is a rapidly increasing problem that in a few years could make infections impossible to treat and bring the state of medical care back to the pre-antibiotic era from the beginning of the last century. Antimicrobial peptides (AMPs) have a huge potential as new therapeutics against infectious diseases as they are less prone to induce resistance due to their fast and non-specific mechanism of action. The aim of FORMAMP is to explore a number of innovative formulation and delivery strategies based on nanotechnology in order to improve the efficiency and stability of AMPs in clinical development. Functional delivery systems that can be applied directly on the infected site will be developed for treatment of infections in skin and burn wounds, as well as lung infections caused by Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa and Mycobacterium tuberculosis (MTB). Formulation and delivery strategies to prevent and treat biofilm formation related to these conditions will be developed. Different nanoformulation platforms, particularly promising for peptide delivery, controlled release strategies and technologies against proteolytic degradation of peptides will be evaluated in the project. These include lipid-based systems such as lipidic nanocapsules, polymer-based structures such as dendrimers and microgels as well as nanostructured mesoporous silica. The possibility to formulate the nanostructured materials into efficient drug delivery systems such as a topical spray or gel and pulmonary aerosol will be evaluated. The effect of nanoformulated AMPs will be evaluated with state-of-the art in vitro models and in vivo models. The results of this interdisciplinary project will generate efficient treatment strategies combatting one of the largest threats to our health care system today, reducing healthcare costs and expand the growth of European enterprises within the field of pharmaceutics and nanomaterials.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

RISE RESEARCH INSTITUTES OF SWEDEN AB

Address

Brinellgatan 4
501 15 Boras

Sweden

Activity type

Research Organisations

EU Contribution

€ 1 523 012,20

Administrative Contact

Lovisa Ringstad (Dr.)

Participants (15)

LUNDS UNIVERSITET

Sweden

EU Contribution

€ 675 040

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 583 440

UNIVERSITAET ULM

Germany

EU Contribution

€ 515 600

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands

EU Contribution

€ 530 868

Pergamum AB

Sweden

EU Contribution

€ 250 800

LAKEMEDELSVERKET

Sweden

EU Contribution

€ 180 373

SP PROCESS DEVELOPMENT AB

Sweden

EU Contribution

€ 703 492

POLYMER FACTORY SWEDEN AB

Sweden

EU Contribution

€ 353 552

UNIVERSITE D'ANGERS

France

EU Contribution

€ 528 480

CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS

France

EU Contribution

€ 199 680

KUNGLIGA TEKNISKA HOEGSKOLAN

Sweden

EU Contribution

€ 662 040

INHALATION SCIENCES SWEDEN AB

Sweden

EU Contribution

€ 510 637,80

XSPRAY PHARMA AB (PUBL)

Sweden

EU Contribution

€ 367 240

ADENIUM BIOTECH APS

Denmark

EU Contribution

€ 232 810

POLYPEPTIDE LABORATORIES (SWEDEN) AB

Sweden

EU Contribution

€ 128 429

Project information

Grant agreement ID: 604182

Status

Closed project

  • Start date

    1 December 2013

  • End date

    30 November 2017

Funded under:

FP7-NMP

  • Overall budget:

    € 10 348 954,90

  • EU contribution

    € 7 945 494

Coordinated by:

RISE RESEARCH INSTITUTES OF SWEDEN AB

Sweden

This project is featured in...